# Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody

> **NCT05392413** · — · RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- PD-1 Inhibitor

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05392413
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05392413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05392413, "Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05392413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*